Introduction: Glycemic control in participants with insulin-treated diabetes remains
INTRODUCTION
The number of people with diabetes is increasing globally with 90% having type 2 diabetes, a fifth of whom are on insulin treatment. A significant proportion of adults with insulin-treated type 2 diabetes are less than 65 years of age and frequently have poor glycemic control [1, 2] .
Improving glycemia reduces the risk of diabetes complications and is a key management objective [3] . However, intensification of insulin therapy increases the risk of hypoglycemia [4] which is associated with adverse clinical outcome [5] , impacts on quality of life [6] , and increases treatment costs secondary to hospital admissions, ambulance call-outs, and clinic attendance [7] . Glycated hemoglobin (HbA1c), the gold standard for assessment of glycemic control, is unable to reflect hypoglycemic risk or indicate glucose variability, which recent reports suggest are associated with inferior clinical outcome [8, 9] . Detection of hypoglycemia or glucose variability can be difficult with self-monitoring of blood glucose which is usually the main method used for self-management and adjusting insulin therapy.
For participants on intensive insulin therapy, four or more blood glucose tests are required daily to safely and effectively adjust insulin doses. This is not always achieved because of the pain and inconvenience associated with this method of glucose testing [10, 11] . A tool that can support a more comprehensive assessment of glycemia is continuous glucose monitoring; however, current devices are costly, require repeated calibration, and are constantly attached to the patient, all key factors preventing widespread use. There is a need for a new method of glucose monitoring that is affordable and provides clear, comprehensive glucose data with minimal patient inconvenience. [12] .
The aim of our study was to assess the role of this new category of glucose-sensing technology on glycemic control in individuals with type 2 diabetes using intensive insulin therapy or continuous subcutaneous insulin infusion (CSII).
METHODS

Study Design and Participants
We conducted this 6- (intervention participants only) were assessed at 6 months. Patient-reported outcome and quality of life (QoL) measures were assessed using validated questionnaires: Diabetes Distress Scale (DDS) [14] , Diabetes Quality of Life (DQoL) [15] , and Diabetes Treatment Satisfaction (DTSQs and DTSQc) [16] .
Safety endpoints incorporated all adverse events including severe hypoglycemia (requiring third-party assistance) [13] , hypoglycemic events [20] , sensor insertion or sensor wear-related symptoms, diabetic ketoacidosis or hyperosmolar hyperglycemic state episodes, and cardiac events.
Statistical Analysis
This study was powered at 90% to detect a difference of 3.8 mmol/mol (0.35%) in HbA1c between the intervention and control group at 6 months with a 5% significance level as per guidance of the Food and Drug Administration [21] and assuming SD for the change of 0.65 [22] . The intervention group was double the size of the control group resulting in a sample size of 210 participants allowing for a dropout rate of Results presented here are for the full analysis set, which included all randomized participants since there were no pregnancies.
Data analysis was performed by a contract research organization (ICON PLC; Dublin, Ireland, managed by Abbott Diabetes Care) and by Abbott Diabetes Care. We used SAS version 9.2 or higher for all analyses.
The trial is registered with ClinicalTrials.gov (NCT02082184).
Role of the Funding Source
The sponsor designed the study protocol in collaboration with the principal investigator in each country and provided all study materials.
The sponsor was involved in collecting data and reporting results, but was not involved in the authors' interpretation or text writing. The sponsor also gave approval to submit for publication. The corresponding author had full access to all the data in the study and, together with all authors, had final responsibility for the decision to submit for publication.
RESULTS
We recruited 302 participants between March 13 and October 15, 2014; 224 were randomized (149 intervention, 75 controls) after completing the baseline phase ( Fig. 1 ). Prior to randomization 78 participants discontinued, the primary reason for this was failure to meet screening HbA1c criterion. Participants' baseline characteristics are summarized in Table 1 , the full analysis set included 224 randomized participants, and there were no significant differences between groups. In participants aged 65 years or more, the drop in HbA1c was more pronounced for the Table 2 continued 131 (33) 125 (29) 131 ( 56 (15) 54 (13) 56 ( 50 (14) 47 (12) 51 ( 61 (19) 57 (18) 64 ( 62 (22) 58 (23) 65 ( (Table 2) .
A number of glucose variability measures were explored and an improvement for intervention participants was observed (Table 2 and Supplementary Material pp. 8-9 ). Fig. 3) . During the treatment phase (day 15 onwards) average sensor-scanning frequency was 8.3 ± 4.4 (mean ± SD) times/day (median 6.8), i.e., double the frequency of blood glucose testing (Fig. 3) . There was no significant difference in the number of scans performed by those \65 years and C65 years of age [8.1 ± 4.6 (median 6.8) and 8.5 ± 4.1 (median 6.9), respectively, p = 0.6627].
There was no correlation between frequency of sensor scanning and reduced time in hypoglycemia or change to HbA1c. Device use for the intervention group (n = 138) was 88.7 ± 9.2% (defined as the percentage of data Self-monitoring of blood glucose frequency for control participants was 3.9 ± 1.5 test/day (median 3.9) at baseline and this rate was maintained until study end [3.8 ± 1.9 (median 3.9), Fig. 3 ]. Control group participants \65 years performed less blood glucose monitoring tests (2.78 ± 1.08 test/day) than those C65 years (3.46 ± 0.94), p = 0.0247.
At baseline, 95% of participants used an insulin pen device or syringe for intensive insulin therapy, with the remainder (5%) on CSII (Table 1) The system was used for 6 months by intervention participants and worn (blinded) for 4 weeks by control participants (n = 224). In total, serious adverse or adverse events (n = 515) were experienced by 114 (76.5%) intervention and 47 (62.7%) control participants.
There were no serious adverse events related to the device or study procedure. None of the severe hypoglycemic episodes [13] or hypoglycemic adverse events were associated with the device.
Three participants (one intervention, two controls) experienced an adverse event leading to withdrawal from the study; none were associated with the device.
Six (4.0%) intervention participants reported nine device-related adverse events (two severe, six moderate, and one mild). These were sensor-adhesive reactions, primarily treated with topical preparations. All were resolved at study exit.
There were no reported events of diabetic ketoacidosis or hyperosmolar hyperglycemic state. Seven cardiac events were reported for four (2.7%) intervention and three (4.0%) control participants (none were considered to be related to study procedures or the device).
Anticipated symptoms refer to those typically expected using a sensor device and equate to symptoms normally experienced with blood glucose finger-stick testing, e.g., pain, bleeding, bruising. There were 158 anticipated sensor insertion site symptoms observed for 41 (27.5%) intervention and 9 (12.0%) control participants. These symptoms were primarily (63%) due to the sensor adhesive (erythema, itching, and rash) and resolved without medical intervention. Adverse events and anticipated symptoms associated with the insertion of the sensor and sensor wear are summarized in Table 3 There is a paucity of data on continuous glucose monitoring (CGM) use in type 2 diabetes and, to our knowledge, no recent randomised, controlled studies in this population using intensive insulin therapy.
Available data for CGM use in those using oral glucose-lowering medication or basal insulin with higher baseline HbA1c values indicate they are more likely to show benefit with a reduction in this clinical marker [24] [25] [26] . However, hypoglycaemia was not an endpoint in these studies, and exposure to hypoglycaemic risk is much less in treatment regimens excluding prandial insulin. Reductions in hypoglycaemic markers generally require de-escalation of glucose-lowering therapy [27] with less stringent glucose targets [28] . In the intervention group, HbA1c level improved with significantly reduced exposure to hypoglycaemia.
Reductions in hypoglycemia in the intervention group were present across all age groups, particularly significant in those aged proportions may not be apparent in the total insulin dose [29] . Given the association of hypoglycemia with adverse clinical outcome, including enhanced risk of cardiovascular events, increased hospital admissions, and reduced survival [5, 7] , these results for multiple hypoglycemia-related secondary endpoints highlight the effectiveness and safety of this technology and its potential for improving glycemic control. Detection of In addition to benefiting from less time in hypoglycemia compared with the control group, intervention participants showed improvement in glucose variability [30] and LBGI, a specific risk marker for hypoglycemia [31] . These findings can be partially explained by the documented association between hypoglycemia and glucose variability [30, 31] . The reduction in hypoglycemic exposure in the intervention group may offer additional clinical benefits [8, 9] . A significant improvement in HbA1c was detected in those younger than 65 years.
Although the reasons for this finding are not entirely clear we hypothesize that the convenience associated with sensor glucose readings, compared with blood glucose testing, prompted more frequent testing. This supports a recent study reporting younger participants as being ''too busy'' for finger-stick testing [32] . The overall impact of these two approaches to care was no effect on HbA1c.
These findings may have future clinical implications as past studies show worse glycemic control in younger participants with type 2 diabetes [3, 4] and this new sensor-based technology may be helpful for these participants.
However, no adjustments were made for multiple testing by subgroup and future work is required to confirm this observation. and perceived control over diabetes [33] .
Our study results support those of a recent randomized control trial comparing use of this technology with blood glucose testing in adults with well-controlled type 1 diabetes, which also demonstrated superior reduction in hypoglycemia without deterioration of HbA1c and improved treatment satisfaction [34] .
Limitations of this work include the absence of a treatment algorithm for modifying insulin therapy. 
